The Interplay between Cardiovascular Risk, Cardiovascular Events, and Disease Activity in Primary Sjögren’s Syndrome: Is Uric Acid the Missing Link?

Alunno, Alessia; Carubbi, Francesco; Mariani, Francesco; Martini, Cecilia; Campanozzi, Elena; Ferri, Claudio

doi:10.3390/nu15071563

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…General preventive measures for cardiovascular manifestations represent the main treatment strategy in pSS patients as well. Having no specific recommendations for pSS patients with cardiovascular involvement, individualized treatment for each condition is recommended, according to the existing international guidelines [ 281 ].…”

Section: Extraglandular Manifestationsmentioning

confidence: 99%

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

Mihai

Căruntu

Jurcuţ

et al. 2023

JPM

View full text Add to dashboard Cite

Extraglandular manifestations (EGMs) in primary Sjogren’s syndrome (pSS) represent the clinical expression of the systemic involvement in this disease. EGMs are characterized by a wide heterogeneity; virtually any organ or system can be affected, with various degrees of dysfunction. The existing gaps of knowledge in this complex domain of extraglandular extension in pSS need to be overcome in order to increase the diagnostic accuracy of EGMs in pSS. The timely identification of EGMs, as early as from subclinical stages, can be facilitated using highly specific biomarkers, thus preventing decompensated disease and severe complications. To date, there is no general consensus on the diagnostic criteria for the wide range of extraglandular involvement in pSS, which associates important underdiagnosing of EGMs, subsequent undertreatment and progression to severe organ dysfunction in these patients. This review article presents the most recent basic and clinical science research conducted to investigate pathogenic mechanisms leading to EGMs in pSS patients. In addition, it presents the current diagnostic and treatment recommendations and the trends for future therapeutic strategies based on personalized treatment, as well as the latest research in the field of diagnostic and prognostic biomarkers for extraglandular involvement in pSS.

show abstract

Section: Extraglandular Manifestationsmentioning

confidence: 99%

The Spectrum of Extraglandular Manifestations in Primary Sjögren’s Syndrome

Mihai

Căruntu

Jurcuţ

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Since our first document TIMES TO ACT was mainly dedicated to arterial hypertension and hypercholesterolemia, in the document STRUGGLE FOR we will focus more on diabetes and smoking, among other risk factors [ 27 , 28 ].…”

Section: Struggle Formentioning

confidence: 99%

STRUGGLE FOR. Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023 for better control of classical modifiable risk factors in clinical practice

Filipiak,

Barrios,

Ferri

et al. 2023

Cardiol J.

View full text Add to dashboard Cite

The progress in pharmacotherapy that has been made in recent years, including the introduction of very effective and safe lipid-lowering and antihypertensive drugs, has not yet translated into the expected universal control of blood pressure, lipid disorders and diabetes. In the STRUGGLE FOR Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023, experts from five countries recounted several points about the paradigms of cardiological and cardiometabolic care for better control of classical modifiable risk factors in the year 2023. It is believed herein, that the need to intensify treatment, actively search for patients with cardiovascular risk factors, especially with arterial hypertension, hypercholesterolemia and diabetes, should go hand in hand with the implementation of the latest therapy, based on single pill combinations including proven, effective antihypertensive, lipid-lowering and antidiabetic molecules, many of which are listed in the present document. There is a need to use both new technological concepts, completely new drugs, as well as novel treatment concepts such as metabolic treatment in coronary artery disease, try to intensify the fight against smoking in every way, including the available range of drugs and procedures reducing the harm. This approach will provide substantially better control of the underlying cardiovascular risk factors in countries as varied as Italy, Poland, Spain, Uzbekistan and Vietnam.

show abstract

“…The MedDiet seems to also be beneficial for those with chronic inflammatory diseases, including primary Sjögren's syndrome. Alunno et al [17] reports that a MedDiet with a low purine content could significantly reduce the serum levels of uric acid (SUA), which, in Sjögren's syndrome, appears to raise the risk of interstitial lung disease (ILD) and cardiovascular disease (CVD). In a narrative review, Di Majo et al [18] reviewed the effects of both the Mediterranean and ketogenic diets on people's immune systems, neuroinflammation, and redox balance.…”

mentioning

confidence: 99%